Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Henan, People's Republic of China.
Henan Key Laboratory of Molecular Medicine, Zhengzhou University, Henan, People's Republic of China.
Int J STD AIDS. 2024 Apr;35(5):326-336. doi: 10.1177/09564624231220424. Epub 2023 Dec 12.
Influenza vaccination of person living with HIV (PLWH) is a powerful means to tackle severe clinical outcomes. Few data on two doses of influenza vaccine in PLWH are available. To evaluate the immunogenicity and safety of two doses of vaccine as compared with single dose in PLWH, we searched Pubmed, Embase, and web of science databases for relevant articles (January 2009 to April 2023). Pooled SMD or RR and 95% CI were calculated. A total of 2436 participants from 14 studies were included. Compared to single dose influenza vaccine regimen, the pooled RR of seroprotection and seroconversion for two doses of vaccines was 1.14 (95%CI: 1.08-1.21) and 1.25 (95%CI: 1.16-1.34), respectively; the SMD of GMT was 0.42 (95%CI: 0.35, 0.49). Regarding safety, the fever risk in PLWH receiving two doses of vaccine was 3.42 fold higher than that of single dose vaccine, and the risk of myalgia had a quarter reduction. No serious vaccine-related adverse events were reported. Collectively, two doses of the vaccine are associated with a better immunogenicity and an acceptable safety in PLWH. Two doses of the adjuvant vaccination might be a superior vaccination regimen.nation regimen.
艾滋病毒感染者（PLWH）接种流感疫苗是应对严重临床结局的有力手段。关于 PLWH 接种两剂流感疫苗的数据很少。为了评估两剂疫苗与单剂疫苗相比在 PLWH 中的免疫原性和安全性，我们检索了 Pubmed、Embase 和 web of science 数据库中的相关文章（2009 年 1 月至 2023 年 4 月）。计算了汇总 SMD 或 RR 及其 95%CI。共有来自 14 项研究的 2436 名参与者纳入研究。与单剂流感疫苗方案相比，两剂疫苗的血清保护和血清转化率的汇总 RR 分别为 1.14（95%CI：1.08-1.21）和 1.25（95%CI：1.16-1.34）；GMT 的 SMD 为 0.42（95%CI：0.35，0.49）。关于安全性，接受两剂疫苗的 PLWH 发热风险是单剂疫苗的 3.42 倍，肌痛风险降低了四分之一。没有报告严重的疫苗相关不良事件。总之，两剂疫苗在 PLWH 中具有更好的免疫原性和可接受的安全性。两剂佐剂疫苗可能是一种更好的疫苗接种方案。
